MTNB Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Valuation Metrics

The current forward P/E ratio for Matinas BioPharma Holdings Inc (MTNB.A) is -0.41, compared to its 5-year average forward P/E of -4.33. For a more detailed relative valuation and DCF analysis to assess Matinas BioPharma Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.33

Current PE

-0.41

Overvalued PE

-0.70

Undervalued PE

-7.96

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.66

Current EV/EBITDA

-0.04

Overvalued EV/EBITDA

0.11

Undervalued EV/EBITDA

-5.43

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

86.52

Current PS

0.00

Overvalued PS

267.84

Undervalued PS

-94.79

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MTNB News & Events

Events Timeline

No data

News

4.5

2025-08-18Benzinga

US Stocks Show Varied Performance; Riskified Shares Decline Following Q2 Earnings Report

5.0

2025-03-11Newsfilter

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

5.0

2025-03-11Business Insider

Matinas BioPharma appoints Murphy, Neugeboren to board of directors

People Also Watch

Frequently Asked Questions

What is Matinas BioPharma Holdings Inc (MTNB) stock price today?

The current price of MTNB is 0.6437 USD — it has decreased -11.3 % in the last trading day.

What is Matinas BioPharma Holdings Inc (MTNB)'s business?

Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.

What is the price predicton of MTNB Stock?

Wall Street analysts forecast MTNB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MTNB is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Matinas BioPharma Holdings Inc (MTNB)'s revenue for the last quarter?

Matinas BioPharma Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Matinas BioPharma Holdings Inc (MTNB)'s earnings per share (EPS) for the last quarter?

Matinas BioPharma Holdings Inc. EPS for the last quarter amounts to -0.28 USD, decreased -67.06 % YoY.

What changes have occurred in the market's expectations for Matinas BioPharma Holdings Inc (MTNB)'s fundamentals?

The market is revising No Change the revenue expectations for MTNB for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -62.36%.

How many employees does Matinas BioPharma Holdings Inc (MTNB). have?

Matinas BioPharma Holdings Inc (MTNB) has 3 emplpoyees as of January 10 2026.

What is Matinas BioPharma Holdings Inc (MTNB) market cap?

Today MTNB has the market capitalization of 4.12M USD.